Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pink Sheet Podcast: Makena Hearing Take-Aways, Industry’s Accelerated Approval Failings, US FDA Claims Enforcement

Executive Summary

Pink Sheet reporters and editors discuss lessons from the public hearing on the proposed withdrawal of the preterm birth prevention drug Makena, FDA Commissioner Califf’s opinion that industry is not meeting expectations with accelerated approval confirmatory studies, and agency efforts to clarify that staff is paying attention to comparative claims in product ads.

You may also be interested in...

Pink Sheet Podcast: RSV Vaccine Questions, Lilly Lowers Insulin Cost, Orphan Drug Act Changes

Pink Sheet reporters and editors discuss US FDA advisory committee members’ concerns about two proposed RSV vaccines, Lilly’s plan to lower the cost of its insulin products, proposed changes to the Orphan Drug Act, and the departure of the influential leader of the FDA’s neuroscience office.

Publisher’s Spotlight: Citeline Awards 2023 Finalists Announced

We are delighted to announce the shortlist for the seventh annual Citeline Awards, recognizing clinical and research excellence across the biopharmaceutical, CRO and diagnostics industries.

Pink Sheet Podcast: Limiting Medicare Price Negotiation, More US FDA Adcomm And COVID-19 Vaccine Concerns

Pink Sheet reporters and editors discuss the impact of PhRMA’s new push to limit Medicare price negotiations, Congress’ interest in FDA advisory committee reforms, and concerns about the COVID-19 vaccine strain selection process.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts